title: [A case of malignant melanoma from the esophagus responding to weekly paclitaxel therapy].
abstract: A 44-year-old man had a tumor in the lower thoracic esophagus at a health check, and was initially diagnosed as an undifferentiated carcinoma of the esophagus by the esophago-gastric endoscope. Although curative chemoradiotherapy was scheduled after the diagnosis, the interim evaluation revealed that the tumor was malignant melanoma of the esophagus with right renal metastasis. Since then, CVD (cisplatin, vindesine and dacarbazine) therapy, palliative radiotherapy and DAC-Tam (dacarbazine, nimustine, cisplatin and tamoxifen) therapy were carried out, but all of them proved ineffective, and multiple newly metastatic lesions appeared in liver and lymph nodes. Oral intake was impossible because of progressing stricture of the esophagus. As a fourth-line therapy, weekly paclitaxel therapy was started, and his oral intake was improved after the second course. He received the therapy as an outpatient for four months. After the third course, tumor lesions were evaluated as a partial response by CT. Consequently, five courses of the therapy were performed with modest adverse effects. Weekly paclitaxel therapy was reasonably safe as reported in other reports and considered to be a promising regimen for malignant melanoma of the esophagus.
authors.affiliation: Dept. of Clinical Oncology, Institute of Development, Aging and Cancer and Tohoku University Hospital, Tohoku University.
authors.forename: Yuichi
authors.initials: Y
authors.lastname: Kakudo
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshioka
authors.forename: Santaro
authors.initials: S
authors.lastname: Noguchi
authors.forename: Masahito
authors.initials: M
authors.lastname: Hanada
authors.forename: Kazunori
authors.initials: K
authors.lastname: Otsuka
authors.forename: Masato
authors.initials: M
authors.lastname: Sakayori
authors.forename: Natsuko
authors.initials: N
authors.lastname: Chiba
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Shibata
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Kato
authors.forename: Hideki
authors.initials: H
authors.lastname: Shimodaira
authors.forename: Hisatsugu
authors.initials: H
authors.lastname: Ohori
authors.forename: Shin
authors.initials: S
authors.lastname: Takahashi
authors.forename: Masanobu
authors.initials: M
authors.lastname: Takahashi
authors.forename: Gengo
authors.initials: G
authors.lastname: Yamaura
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Yasuda
authors.forename: Chikashi
authors.initials: C
authors.lastname: Ishioka
mesh_terms: D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D008113:Liver Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D008198:Lymph Nodes / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D017239:Paclitaxel / Q000008:administration & dosage*; D011788:Quality of Life
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel